Biomarker-based Immunoassays Market: as Roche Diagnostics Core Lab CHF 8.00 Billion FY2024 with 8 to 9% underlying growth at constant exchange rates confirms that the reagent pull-through model compounds biomarker immunoassay revenue across cardiac, oncology, and thyroid test categories without proportional new instrument placements, so the April 2024 FDA Breakthrough Device designation for Roche Elecsys pTau217 and the Fujirebio Lumipulse FDA 510(k) clearance in May 2025 open the largest single new biomarker immunoassay test category since high-sensitivity troponin, and so Abbott Alinity i organic growth of 4.5 to 8.8% in 2024 demonstrates that multi-platform competition for hospital laboratory formulary position drives sustained installed base reagent revenue expansion above the total market growth rate.

The global biomarker-based immunoassays market size was USD 7.49 Billion in 2025 and is expected to register a revenue CAGR of 7.5% during the forecast period. Market revenue growth is driven by factors such as the expanding clinical and research utilisation of immunoassay platforms for quantitative biomarker detection across oncology, cardiac, neurological, thyroid, and infectious disease categories, the compounding reagent pull-through revenue model of closed-system immunoassay platforms that grows biomarker test volume per installed instrument above market growth rates, as well as the emergence of next-generation neurological biomarker immunoassay categories anchored by the April 2024 Roche Elecsys pTau217 FDA Breakthrough Device designation and the May 2025 Fujirebio Lumipulse FDA 510(k) clearance that open a new high-value blood-based Alzheimer disease diagnostic immunoassay revenue stream. The first driving factor is the Roche Core Lab CHF 8.00 Billion FY2024 revenue with 8 to 9% underlying growth at constant exchange rates, driven by immunodiagnostic products including cardiac tests, oncology tumour marker tests, and thyroid function assays, confirming the structural compounding of reagent pull-through revenue at the existing cobas immunoassay platform installed base. Roche disclosed in its 2024 Annual Report that Core Lab revenues rose 3% to CHF 8.00 Billion from CHF 7.75 Billion in 2023, representing approximately 56% of Roche Diagnostics total revenues, with immunodiagnostic products growing 9% within Core Lab at constant exchange rates. The second driving factor is Abbott Laboratories Alinity i CMIA platform adoption generating growing reagent and consumable revenue across the installed laboratory customer base. Abbott disclosed in its FY2024 10-K that Core Laboratory Diagnostics sales excluding COVID-19 testing increased 4.5% organically in Q3 2024 led by continued Alinity platform adoption, with US Core Laboratory Diagnostics growing 8.8% organically in Q2 2024. The third driving factor is the April 2024 FDA Breakthrough Device designation for Roche Elecsys pTau217, enabling accelerated FDA review for the first blood-based immunoassay targeting phosphorylated tau-217 as a diagnostic biomarker for Alzheimer disease in a clinical laboratory format, opening the largest prospective new biomarker immunoassay category in the market. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way each Roche Elecsys or Abbott Alinity i immunoassay platform installation at a hospital core laboratory or reference laboratory compounds its biomarker test revenue as each new assay added to the laboratory formulary generates incremental reagent consumable revenue from the same instrument without requiring a new capital placement or a new operator training cycle, which allows Roche and Abbott to expand biomarker immunoassay revenue at existing accounts through test menu additions rather than solely through new instrument placements. Once a hospital core laboratory has standardised its immunoassay operations on the cobas e platform or the Alinity i system and operators have been validated on the reagent workflows, adding a new Elecsys pTau217 or Alinity i NT-proBNP assay to the formulary is an administrative decision that generates incremental reagent revenue at the existing instrument without a new capital event or a workflow disruption, so each quarterly test menu expansion by Roche or Abbott adds to the per-account revenue at all installed accounts simultaneously rather than requiring sequential individual account commercial conversations. As a result, biomarker immunoassay revenue concentrates around the platform providers with the broadest validated biomarker test menus at each installed laboratory, and the forecast tilts toward Roche cobas e and Abbott Alinity i rather than toward standalone ELISA or multiplex platforms that require separate instrument purchases and operator validation cycles for each new biomarker assay. For instance, in March 2025, Roche introduced an advanced automated immunoassay system incorporating high-sensitivity chemiluminescent technology for improved detection of low-concentration oncology and infectious disease biomarkers, extending the Roche cobas biomarker immunoassay menu into high-sensitivity applications where the existing cobas e 801 generation cannot achieve equivalent detection thresholds, one of more than a dozen Roche cobas biomarker menu expansions since 2022 that compound within the established installed base. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the compound growth mechanism of the Roche cobas e immunoassay platform's biomarker test menu expansion, where each new Elecsys assay added to the cobas e formulary generates incremental reagent revenue at every installed cobas e system globally without requiring a new instrument placement or a new reagent supply agreement, compounding the reagent pull-through revenue base as the biomarker test menu broadens across cardiac, oncology, thyroid, and neurological categories. Roche disclosed in its 2024 Annual Report that Core Lab revenues rose 3% to CHF 8.00 Billion, with the underlying Core Lab business growing 8 to 9% at constant exchange rates excluding COVID-19 product revenues, confirming base immunoassay biomarker business growing above the total reported rate as cobas immunoassay platform adoption expands and the Elecsys biomarker test menu broadens. Roche in March 2025 introduced an advanced automated immunoassay system incorporating high-sensitivity chemiluminescent immunoassay technology capable of identifying low-concentration biomarkers with improved analytical accuracy in oncology and infectious disease applications, extending the Roche immunoassay portfolio beyond the established cardiac and thyroid biomarker categories. In April 2024, the FDA awarded Breakthrough Device designation to the Roche Elecsys pTau217 plasma biomarker test for Alzheimer disease, enabling accelerated FDA review for what would be the first Roche-branded blood-based immunoassay specifically targeting phosphorylated tau-217 as a diagnostic biomarker for Alzheimer disease detection in the cobas e clinical laboratory format accessible to hospital core laboratories and reference laboratories globally. The recent pace confirms the trajectory. In July 2024, Roche completed the acquisition of the LumiraDx point-of-care technology business, strengthening its near-patient immunoassay and clinical chemistry capability and extending the cobas reagent ecosystem from the core laboratory into the decentralised testing environment where near-patient cardiac and infectious disease biomarker testing is growing. The effect on the market is a sustained expansion of cobas immunoassay biomarker revenue per installed system as the Elecsys assay menu broadens and premium new categories including neurological biomarkers add high-value test codes to the established reagent base. These are some of the key factors driving revenue growth of the market.

The second driver is the Abbott Alinity i platform's sustained organic revenue growth from hospital clinical laboratory adoption, where each new Alinity i installation generates recurring CMIA reagent pull-through revenue across the cardiac, oncology, thyroid, and autoimmune biomarker test categories that hospital laboratory formularies standardise on the Alinity i system. Abbott disclosed in its FY2024 10-K that Core Laboratory Diagnostics sales excluding COVID-19 testing increased 4.5% organically in Q3 2024 and 8.8% organically in Q2 2024, led by continued Alinity platform adoption, with the Alinity family generating growing reagent revenue through the installed instrument pull-through model. Abbott holds the largest global market share in troponin I assays through its ARCHITECT and Alinity high-sensitivity troponin I platforms, which process over 40 million troponin tests annually across their global installed base per Abbott product documentation, generating the highest single-test-category immunoassay reagent pull-through revenue in the biomarker immunoassay market. The February 2026 FDA clearance of the Alinity i NT-proBNP assay adds heart failure biomarker monitoring to the Alinity i formulary at each installed laboratory account, generating incremental NT-proBNP reagent revenue at accounts where the Alinity i troponin and chemistry menu is already established. The effect on the market is a competitive multi-platform dynamic between cobas e and Alinity i in which both Roche and Abbott sustain above-market biomarker immunoassay reagent revenue growth through test menu expansion at their respective installed bases, preventing either vendor from dominating the incremental menu addition revenue while collectively expanding the total biomarker immunoassay reagent market above the underlying test volume growth rate. These are some of the key factors driving revenue growth of the market.

Abbott Laboratories discloses that its ARCHITECT and Alinity high-sensitivity troponin I platforms process over 40 million troponin tests annually across the global installed base, generating the highest single-test-category immunoassay reagent pull-through revenue in the biomarker immunoassay market. The February 2026 FDA clearance of the Alinity i NT-proBNP assay adds heart failure biomarker quantification to every installed Alinity i account without a new capital event, demonstrating the menu extension compounding mechanism at scale.

The third driver is the emergence of neurological disease biomarker immunoassay categories that represent the largest new commercial opportunity in biomarker-based immunoassays since high-sensitivity cardiac troponin established itself as the guideline-standard cardiac biomarker, with the Roche Elecsys pTau217 Breakthrough Device designation in April 2024 and the Fujirebio Lumipulse FDA 510(k) clearance in May 2025 signalling the regulatory transition of blood-based neurological biomarker testing from research-use-only platforms into cleared clinical immunoassay categories accessible through existing hospital core laboratory and reference laboratory infrastructure. The approximately 6.9 million Americans living with Alzheimer disease and the estimated 10.7 million Americans aged 65 and older projected to have the disease by 2050, documented by the Alzheimer Association 2024 Facts and Figures, establish the addressable diagnostic volume for blood-based neurological biomarker immunoassay testing that would reach the primary care and neurology clinical laboratory channel rather than requiring specialist PET scan or CSF collection procedures at academic memory centres. In October 2024, ADx NeuroSciences and Alamar Biosciences announced a NULISA ultra-sensitive immunoassay platform collaboration for neurological biomarker detection at femtogram concentrations, expanding the ultra-sensitive neurological biomarker immunoassay platform ecosystem beyond Quanterix Simoa into the Alamar Biosciences commercial channel and providing pharmaceutical biomarker research programmes with an additional ultra-sensitive pTau, NfL, and GFAP measurement platform. In July 2025, Spear Bio and Bio-Techne announced a partnership for the SPEAR UltraDetect homogeneous ultra-sensitive immunoassay platform with global access expansion for pharmaceutical and neurological biomarker research, adding a third ultra-sensitive immunoassay platform to the neurological biomarker measurement ecosystem. The effect on the market is a progressive expansion of the biomarker immunoassay addressable revenue opportunity as neurological biomarker immunoassay tests convert from research-use-only platforms at academic centres into cleared clinical IVD tests at hospital core laboratories and reference laboratory networks that can process neurological biomarker test orders from the neurologist and primary care physician ordering community at clinical laboratory scale. These are some of the key factors driving revenue growth of the market.

However, the biomarker-based immunoassays market faces adoption constraints from capital intensity, cross-assay matrix effects, and China healthcare pricing reform that collectively limit revenue growth below the underlying biomarker test volume expansion rate in the forecast period. Because Cobas e series, Alinity i, and Atellica immunoassay analysers are priced between USD 80,000 and USD 400,000 per instrument, requiring hospital laboratory multi-year return-on-investment analysis and long-term reagent supply agreements that extend the instrument placement sales cycle and limit the frequency of installed base replacement, the addressable annual replacement market for the high-throughput segment is constrained by installed base age distribution and available capital budget at institutions that cannot generate the test volume required to justify premium platform economics. Cross-assay interference and matrix effects in complex biological samples are a second constraint, since heterophilic antibodies, rheumatoid factor, and high concentrations of endogenous immunoglobulins reduce the specificity of immunoassay biomarker measurements in affected patient populations, creating clinical performance limitations that require additional confirmatory testing and reduce physician confidence in immunoassay results at the clinical decision threshold, particularly for novel neurological biomarker assays where the clinical decision thresholds are still being validated across diverse patient demographic populations. China healthcare pricing reform is the third constraint, since Roche disclosed that volume-based procurement and immunoassay reimbursement rate reductions in China had a meaningful negative impact on the diagnostics business in 2024, with Roche targeting only low to mid single-digit diagnostics growth in 2025 due to China headwinds, confirming that the world's largest emerging immunoassay market is structurally deflating reagent pricing even for the most clinically validated and guideline-endorsed biomarker immunoassay tests, creating a long-term margin compression dynamic in Asia Pacific that dampens the revenue contribution from what would otherwise be the fastest-growing regional market. These factors substantially limit biomarker-based immunoassays market growth over the forecast period.

Based on product, the global biomarker-based immunoassays market is segmented into reagents and kits, instruments, and software and services. Reagents and kits hold the largest revenue share at approximately 43% of 2025 market revenue, because Roche disclosed in its 2024 Annual Report that 70% of Core Lab CHF 8.00 Billion revenue comes from reagents, confirming the structural dominance of consumable pull-through over instrument capital revenue in the biomarker immunoassay market, which suits the closed-system platform model where each instrument generates 7 to 10 years of recurring reagent revenue above the one-time capital placement value. The instruments segment at approximately 35% captures the initial capital placement revenue from new cobas e 801, Atellica Solution, DxI 9000, and Alinity i system installations at hospital core laboratories and reference laboratory network capital equipment refresh cycles. The ultra-sensitive and multiplex platform segment, encompassing Quanterix Simoa, Meso Scale Diagnostics electrochemiluminescence multiplex systems, Alamar Biosciences NULISA, and Spear Bio UltraDetect, is expected to register the fastest revenue growth rate driven by neurological biomarker and pharmaceutical drug development biomarker research demand, where the femtomolar detection sensitivity of ultra-sensitive platforms exceeds the analytical capability of conventional CLIA and ECL systems for low-abundance pTau, NfL, and GFAP neurodegeneration biomarker quantification.

Cardiac biomarker immunoassay category is expected to account for a significantly large revenue share in the global biomarker-based immunoassays market during the forecast period

Based on biomarker type, the global biomarker-based immunoassays market is segmented into efficacy and pharmacodynamic biomarkers, safety biomarkers, predictive and companion diagnostic biomarkers, and neurological disease biomarkers. Cardiac biomarkers, encompassing high-sensitivity cardiac troponin I and T, NT-proBNP, BNP, myoglobin, and CK-MB immunoassay testing, hold the largest revenue share because the European Society of Cardiology chest pain rapid rule-out guideline mandating 0-hour and 1-hour high-sensitivity troponin protocols drives continuous high-volume troponin immunoassay ordering at emergency departments globally, with Abbott holding the largest global market share in troponin I assays through ARCHITECT and Alinity high-sensitivity troponin I platforms processing over 40 million troponin tests annually per Abbott product documentation. The neurological disease biomarker segment, encompassing pTau217, pTau181, NfL, GFAP, UCH-L1, and Abeta42/40 ratio immunoassay testing for Alzheimer disease and traumatic brain injury, is expected to register the fastest growth rate, driven by the Roche Elecsys pTau217 Breakthrough Device designation and the May 2025 Fujirebio Lumipulse FDA 510(k) clearance creating the clinical immunoassay format for blood-based Alzheimer biomarker testing at hospital core laboratory scale.

Based on regional analysis, the biomarker-based immunoassays market in North America accounted for largest revenue share in 2025, estimated at approximately 49% of global market revenue. The United States leads because it holds the highest per-capita clinical laboratory immunoassay test volume globally, the commercial presence of Abbott Laboratories Core Laboratory Diagnostics with the Alinity platform across the approximately 6,000 US acute care hospitals, the growing Roche cobas e immunoassay installed base at major US reference laboratory networks including Quest Diagnostics and LabCorp, and the emerging neurological biomarker immunoassay market driven by Alzheimer disease diagnosis demand at approximately 6.9 million Americans living with the disease. Abbott disclosed that US Core Laboratory Diagnostics grew 8.8% organically in Q2 2024 excluding COVID-19 testing, driven by Alinity system deployment at US hospital laboratory customers, confirming sustained North American biomarker immunoassay reagent demand growth above the global market rate.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and Italy represent the four largest national biomarker immunoassay markets within Europe. Roche reported Core Lab sales grew across all regions in 2024, with Europe, Middle East and Africa contributing to the global CHF 8.00 Billion Core Lab revenue driven by cardiac, oncology, and thyroid biomarker assays across the European hospital and reference laboratory cobas immunoassay installed base. The EMA and IVDR 2017/746 regulatory framework requiring CE marking for clinical biomarker immunoassay products sustains the competitive position of established IVD manufacturers with existing EU IVDR notified body certification and creates a regulatory barrier that slows entry of new immunoassay platforms from outside the EU. The result is steady rather than rapid European biomarker immunoassay market growth, shaped more by IVDR certification timelines and large reference laboratory consolidation contract cycles than by underlying clinical demand constraints.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. China, Japan, South Korea, and Australia represent the four largest national biomarker immunoassay markets within the region. Japan maintains high immunoassay test volume for thyroid, hepatitis, tumour marker, and cardiac biomarker testing, with Fujirebio Holdings holding significant market positions in oncology tumour marker and neurodegeneration biomarker immunoassay categories including Lumipulse GFAP and pTau assays already approved in Japan and European markets ahead of US commercialisation, leaving more room for Asia Pacific neurological biomarker immunoassay growth than in North America where the initial FDA-cleared market is already being established through Labcorp distribution.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national biomarker immunoassay markets within the region. Brazil's growing private hospital network and expanding reference laboratory infrastructure are increasing adoption of Roche cobas and Abbott Alinity immunoassay platforms, with Roche reporting Latin American organic revenue growth as part of global Core Lab customer area growth across all regions outside China. The indirect effects of Iran-US sanctions on freight costs along South American trade lanes have maintained elevated reagent import cost premiums for immunoassay consumable materials entering Brazilian and Mexican laboratory distribution networks through 2026, suppressing margin expansion at distributors importing from European manufacturing facilities through affected trade routes.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial biomarker immunoassay markets within the GCC. Roche disclosed Core Lab customer area sales grew across EMEA in 2024, with Middle Eastern hospital and reference laboratory customers contributing to global 3% Core Lab revenue growth as GCC Vision 2030-funded tertiary hospital laboratory capacity expansion increases the addressable market for cobas immunoassay platform placement. South Africa is the most established market on the continent for automated biomarker immunoassay platforms, with private hospital group core laboratories at Mediclinic, Netcare, and Life Healthcare deploying Roche cobas and Abbott ARCHITECT immunoassay systems, while Gulf state newly commissioned tertiary hospital laboratories are building out their core immunoassay infrastructure in parallel with Vision 2030 hospital construction programmes.